The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon
30 HAARBA'A ST, SOUTH TOWER, TEL AVIV 6473926, ISRAEL
Tel:
Work +972 73 788 0882
Fax:
Fax +972 73 788 0883
Web:
www.liadwhatstein.com

Israel

Healthcare and life sciences
Healthcare and life sciences - ranked: tier 2

Liad Whatstein & Co. Law Office

Liad Whatstein & Co. Law Office is a high-quality IP boutique, which is regularly involved in IP disputes, particularly patent disputes, in the pharmaceuticals sector. Headed by Liad Whatstein, the team has handled complex disputes for many of the world's largest pharmaceutical companies, such as Merck, Pfizer, and Sanofi. Acting for Sanofi, the team is involved in a Supreme Court appeal concerning a District Court finding that the company committed fraud on the Patent Office. Further, Whatstein is representing Pfizer in a patent infringement proceeding against Unipharm concerning the client's drug, Viagra. Whatstein is also assisting Merck with ongoing opposition proceedings against Teva in relation to a diabetes drug. The team has also handled IP disputes for Novartis, Eli Lilly, and The State of Israel.

[back to top]

Intellectual property: disputes
Intellectual property: disputes - ranked: tier 1

Liad Whatstein & Co. Law Office

The team at Liad Whatstein & Co. Law Office is 'business-minded, well informed and very creative'; moreover, it is 'bold and daring' but also 'doesn't rush too quickly into litigation'. Led by name partner Liad Whatstein, the firm has considerable expertise in patent litigation in the pharmaceuticals sector, and is engaged by a host of multinational pharma companies. Whatstein is acting for Sanofi in a Supreme Court appeal concerning a District Court decision that the client committed fraud on the patent office in connection with its drug, Plavix. Additionally, the team is representing Merck in patent opposition proceedings brought by Teva, and is involved in multiple high-value revocation proceedings for Novartis. Whatstein also handled patent infringement cases for Pfizer and Eli Lilly. Outside of the pharmaceuticals sector, Whatstein and Amira Mangelus are acting for Italian agrochemical manufacturer Finchimica in opposition and infringement proceedings with a ChemChina company. The team is also advising a client in the defence sector on an IP ownership dispute with a sub-contractor.

Leading individuals

Liad Whatstein - Liad Whatstein & Co. Law Office

Next generation lawyers: Intellectual property: disputes

Amira Mangelus - Liad Whatstein & Co. Law Office

[back to top]

Intellectual property: filing/prosecution
Intellectual property: filing and prosecution: patents - ranked: tier 3

Liad Whatstein & Co. Law Office

Intellectual property: filing and prosecution: trade marks and copyrights - ranked: tier 2

Liad Whatstein & Co. Law Office

Liad Whatstein & Co. Law Office is perhaps best known for its IP litigation capabilites, though the firm also maintains an active trade mark management and application practice, and has experience with patent applications and patent term extensions. The team is led by Liad Whatstein, who helps to manage the Israeli trade mark portfolio of clients, including Hearst Corporation, Grey Goose, Viacom, Hyundai, Paramount Pictures, FIFA, and Merck. Whatstein's IP disputes practice is particularly standout in the pharmaceuticals sector, and this sector experience extends to filing and prosecution. The team advises clients including Novartis, AbbVie, Lundbeck, and Sanofi. Amira Mangelus is another key contact.

Leading individuals: Intellectual property: filing and prosecution: patents

Liad Whatstein - Liad Whatstein & Co. Law Office

[back to top]


Further information on Liad Whatstein & Co. Law Office

Please choose from this list to view details of what we say about Liad Whatstein & Co. Law Office in other jurisdictions.

Israel

Offices in Tel Aviv

Legal Developments in Israel

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • INVESTMENT OPPORTUNITIES FOR HNWIs IN ISRAEL’S HI-TECH ECOSYSTEM

    Accredited investor funding platforms for innovative tech scale-ups offer more choice and without having to commit a large chunk of capital upfront, the risk is diluted.
  • Perhaps the QuadragaCX Story Will Have a Happy Ending

    While there are the aficionados who will say that cryptocurrencies will free us of the chains of the global financial institutions, on the occasions when the world of cryptocurrencies intersects with the world in which most of us live, the news is generally bleak. While you may not know one side of a Bitcoin from the other, you probably know that its value has crashed over the last 13 months, you may even have heard about some of some of the larger cryptohacks (that is computer heists through which digital currencies belonging to investors are stolen from crypto trading exchanges). And over the last week or so, you may have read on mainstream news sites about the death of Gerald Cotton the CEO of Canada’s largest cryptoexchange QuadragaCX. The death of the CEO of a company that few had previously heard of, was news of course, because in his passing he had taken the passwords to the accounts of his customers with him. The result of this being that about $140 million of their money was stuck somewhere between this world and the celestial ether in which Mr. Cotton now resides. Of course, it wasn’t quite told like that. We were fed terms such as “private keys,” lack of “multi-signature protection,” “cold storage wallets” and more readily understandable – “cryptofraud”. Again!
  • Israel Chapter in The Virtual Currency Regulation Review

    Earlier this year, the Israel Tax Authority (ITA) issued two circulars, one on the taxation of digital tokens and the second addressing the taxation of utility tokens in initial coin offerings (ICOs). Additionally, in March, the Israel Securities Authority (ISA) released a detailed interim report by the Committee for the Regulation of Public Offerings of Decentralized Cryptocurrency Coins (Report) (with a follow-up report due to come out around October 2018). Moreover, it is expected that before the end of 2018, legislation will come into force that for the first time will see Israeli primary legislation define virtual currencies as financial assets and mandate licensing for related services, as is later discussed in detail.
  • Spring is coming for real estate registration in Israel

    Israel may be the “Start-up Nation” and a world-renowned center of technological innovation, yet for many years the procedures and conduct of the Israeli Land Registry have been trapped in the past.
  • PLATFORMS FOR HIGH NET WORTH INVESTORS IN ISRAELI HIGH-TECH

    Israeli hi-tech and its sources of funding have grown and diversified tremendously since the bubble burst in 2001 and over the last decade since the height of the financial crisis in 2007-2008.
  • NONDISCRIMINATION IN 5G STANDARDS

    Nondiscrimination has been the neglected stepchild of the FRAND commitment. Patent owners participating in standards organizations typically commit to license their technology on “fair, reasonable, and nondiscriminatory (“FRAND”) terms.”
  • Crash Course on Non-Disclosure Agreements

    Non-disclosure agreements are a crucial, but often overlooked, tool in allowing startup companies to grow, build strategic partnerships and explore new business relationships necessary to develop their product or bring it to market. These agreements are often short (sometimes only a page or two) and lead many founders to forego legal advice to get past this "formality" and begin working with the other party to the NDA. Yet, NDAs are important agreements with potentially far-reaching implications for the protection of a company's confidential information and intellectual property, and mishandling of NDAs can come back to haunt a startup years later.
  • Advocates Eli Greenbaum and Ezra Gross of Yigal Arnon & Co. in The Lawyer Special Report editorial

    An interview-style piece in The Lawyer, Law in Israel: moving beyond tech, quoting Eli Greenbaum and Ezra Gross:
  • Publication of Adv. Adrian Daniel's Commentary in Private Banker International on GDPR & Blockchain

    Publication of Adv. Adrian Daniel's Commentary in Private Banker International on GDPR & Blockchain.
  • Article in MEA Markets on GDPR & Israeli Law

    GDPR & ISRAELI PRIVACY LAW - KEY DIFFERENCES Yoheved Novogroder-Shoshan & Miriam Friedmann of Yigal Arnon & Co. outline the key differences between GDPR & Israeli Privacy Law.  mea_markets_-_gdpr__israeli_law_-_key_differences_14.05.2018